Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,125.8
7.2 (0.23%)

 

  • STI Straits Times Index
    3,125.8
    7.2 (0.23%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,558.5
    -6.3 (-0.40%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,839.0
    21.9 (0.08%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,561.0
    -5.2 (-0.15%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,861.6
    -13.3 (-0.05%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,015.0
    -19.5 (-0.32%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 568.8M
  • Value: 383.9M
  • Rise: 140
  • Fall: 123
  • Unch: 501

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Shen Yao0.006-
Tuan Sing0.540+0.065
MarcoPolo Marine0.028-
AP Strategic0.003+0.001
Trendlines0.114+0.003
Rex Intl0.189+0.004
YZJ Shipbldg SGD1.410+0.030
Singtel2.310+0.010
Adventus0.010-0.002
Intl Cement0.035+0.001

World Indices

World Indices
Name Last Change
Nasdaq 14,271.7 +18.5
HSI 28,839.0 +21.9
HSCEI 10,678.7 +4.8
Jakarta 6,015.0 -19.5
Nikkei 225 28,866.4 -8.4
SSE Comp 3,561.0 -5.2
Shanghai A 3,732.6 -5.5
Shanghai B 253.4 +1.8
KOSPI 3,288.0 +11.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

PFIZER INC PFIZER
Updated on 23 Jun 2021 (End of trading day)
Last (USD): 39.050 Change: -0.560 High: 39.660 Remarks: -
Change (%): -1.41 Low: 38.975
Open 39.630 Yesterday's Close 39.61
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 22,015,910 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 1.71785 Trailing EPS (USD) e 1.98135 NAV (USD) b 12.2586
PE a 22.732 Trailing PE f 19.709 Price / NAV b 3.1855
Dividend (USD) d 1.521612 Cash In Hand (USD) g 0.3158 Issued & Paid-up Shares c 5,597,690,000
Dividend Yield (%) d 3.897 Price / Cash In Hand g 123.654 Treasury Shares h 3,851,000,000
Market Cap (M) 218,589.794 Enterprise Value (M) 244,866.794
Piotroski F Score 4 Exchange Code PFE Par Value ( $ ) n.a.
52 Weeks Volatility (%) 23.88 Free Float (%) -
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 20 May 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 14 May 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference PFIZER INC NYSE 218,589.794 22.732 19.709 3.1855 3.897
Industry Pharmaceuticals: Major NYSE 114,210.887 32.391 30.216 5.4761 2.100
Local Peer JOHNSON & JOHNSON NYSE 428,269.842 29.106 28.334 6.5053 2.446
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 227,931.673 28.070 28.560 4.5115 2.059
Local Peer ELI LILLY AND COMPANY NYSE 208,204.545 33.616 34.174 30.1804 1.360
Local Peer ABBVIE INC NYSE 201,349.080 44.194 39.604 14.6864 4.243
Local Peer MERCK & CO INC NYSE 191,373.095 27.080 27.230 7.1024 3.279
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 145,786.272 - - 3.8768 2.832
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 144,729.524 22.460 21.529 15.6565 1.648
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 100,252.637 13.599 14.766 4.8882 5.192
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 52,685.991 14.861 14.861 1.1254 4.602
Local Peer ORGANON & CO NYSE 7,478.722 3.462 3.462 1.3632 -
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 6,359.022 - - -23.0417 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 3,217.809 10.547 8.308 2.1131 -
Other Local Peers ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 152,228.809 47.263 38.015 10.5495 2.363
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 131,323.366 9.355 9.355 1.7036 2.573
Global Peer WUXI APPTEC HKEx 515,607.815 155.352 108.232 12.3174 0.202
Global Peer ROYALTY PHARMA PLC NASDAQ 25,614.055 26.270 26.330 5.2464 0.455
Global Peer HANSOH PHARMA HKEx 200,471.547 69.447 69.447 9.4587 0.228
Global Peer VIATRIS INC NASDAQ 17,126.712 - - 0.7998 -
Global Peer INNOVENT BIO HKEx 133,397.505 - - 12.8148 -
Global Peer CANSINOBIO-B HKEx 104,324.920 - - 14.5124 -
Global Peer REPLIGEN CORP NASDAQ 10,592.176 176.754 133.133 6.8064 -
Global Peer CUREVAC NV NASDAQ 10,597.780 - - - -
Other Global Peers SINOPHARM (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), JUNSHI BIO (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), CMS (HKEx), AKESO-B (HKEx), SH PHARMA (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), IMMUNITYBIO INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), INNOCARE-B (HKEx), ALLAKOS INC (NASDAQ), BAIYUNSHAN PH (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), SIMCERE PHARMA (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINARES PHARMA (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CHINAGRANDPHARM (HKEx), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), EVEREST MED-B (HKEx), CSTONE PHARMA-B (HKEx), IGM BIOSCIENCES INC (NASDAQ), OPKO HEALTH INC (NASDAQ), HENLIUS (HKEx), OCUMENSION-B (HKEx), CARSGEN-B (HKEx), QUANTERIX CORPORATION (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HEPALINK (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), SSY GROUP (HKEx), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ANTENGENE-B (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), UNITED LAB (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), GENERATION BIO CO (NASDAQ), KRONOS BIO INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), SCICLONE PHARMA (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), TONGRENTANGCM (HKEx), REPARE THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), Kimia Farma Tbk. (IDX), PHIBRO ANIMAL HEALTH CORP (NASDAQ), ESSA PHARMA INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), CKLIFE SCIENCES (HKEx), PHATHOM PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), CRINETICS PHARMACEUTICALS INC (NASDAQ), SHINEWAY PHARM (HKEx), EVOLUS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), VERU INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE-B (HKEx), BOLT BIOTHERAPEUTICS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), PROVENTION BIO INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), Soho Global Health Tbk. (IDX), VECTIVBIO HLDG AG (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), IGBB (Bursa), STARPHARMA HOLDINGS LIMITED (ASX), GRITSTONE BIO INC (NASDAQ), ATHENEX INC (NASDAQ), BEYONDSPRING INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), RACE ONCOLOGY LTD (ASX), ANGION BIOMEDICA CORP (NASDAQ), DURECT CORP (NASDAQ), INOZYME PHARMA INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), KALA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), BSTEAD (Bursa), XOMA CORP (NASDAQ), DAWNRAYS PHARMA (HKEx), FUSION PHARMACEUTICALS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), PHARMA (Bursa), TOT BIOPHARM-B (HKEx), AFT PHARMACEUTICALS LTD (ASX), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), OVID THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), FUSEN PHARM (HKEx), CLEARSIDE BIOMEDICAL INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), HARROW HEALTH INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), IP (SET), 180 LIFE SCIENCES CORP (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), CH BIOTECH SER (HKEx), SATSUMA PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), ZHONGZHIPHARM (HKEx), LANTERN PHARMA INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), GENPREX INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), NOXOPHARM LTD (ASX), AYTU BIOPHARMA INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), IMARA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), IX Biopharma (SGX), CYCLERION THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), CRESO PHARMA LTD (ASX), YUMANITY THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), PROTARA THERAPEUTICS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), ENTERA BIO LTD (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), NEW RAY MEDIC (HKEx), KOTRA (Bursa), PROPHASE LABS INC (NASDAQ), CHARMACY PHAR (HKEx), AERPIO PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Phapros Tbk. (IDX), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), PAK FAH YEOW (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), Hyphens Pharma (SGX), MODERN CHI MED (HKEx), EDESA BIOTECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), EXOPHARM LTD (ASX), ASSERTIO HOLDINGS INC (NASDAQ), NOVA (Bursa), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), INVION LTD (ASX), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), BIOHLDG (Bursa), ADIAL PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), NEP INTERLONG (HKEx), AGEX THERAPEUTICS INC (NYSE American), VIRIOS THERAPEUTICS INC (NASDAQ), MANNATECH INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), EXTRAWELL PHAR (HKEx), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), HOTH THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), NLS PHARMACEUTICS LTD (NASDAQ), SYNAPTOGENIX INC (NASDAQ), SANAI HEALTH GP (HKEx), PURAPHARM (HKEx), SUNZEN (Bursa), VALLON PHARMACEUTICALS INC (NASDAQ), JCT (SET), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), ACRUX (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), MILLENDO THERAPEUTICS INC (NASDAQ), PHARMAXIS (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), CHINA SXT PHARMACEUTICALS INC (NASDAQ), TALI DIGITAL LIMITED (ASX), VIRPAX PHARMA INC (NASDAQ), ISLAND PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.430
-1.09 %
10 Days --1.630
-4.01 %
20 Days -+0.400
+1.03 %
Medium Term Return 3 Months -+3.380
+9.48 %
6 Months 0.390+1.780
+5.82 %
1 Year 99.570+6.730
+328.90 %
Long Term Return 2 Years 101.050-4.380
+222.59 %
3 Years 102.450+2.690
+289.16 %
5 Years 105.010+3.840
+309.15 %
Annualised Return Annualised --
+32.55 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 31.610 - 43.080 Change From 1 Year Low +7.440 % Change From 1 Year Low (%) +23.54
Change From 1 Year High -4.030 % Change From 1 Year High (%) -9.35
2 Years Range 27.880 - 44.561 Change From 2 Years Low +11.170 % Change From 2 Years Low (%) +40.06
Change From 2 Years High -5.511 % Change From 2 Years High (%) -12.37
5 Years Range 27.880 - 46.470 Change From 5 Years Low +11.170 % Change From 5 Years Low (%) +40.06
Change From 5 Years High -7.420 % Change From 5 Years High (%) -15.97
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
23 Jun 2021 39.630 39.660 38.975 39.050 22,015,910 -
22 Jun 2021 39.410 39.690 39.260 39.610 15,970,580 -
21 Jun 2021 38.880 39.480 38.880 39.420 19,478,690 -
18 Jun 2021 39.300 39.440 38.700 38.810 37,542,950 -
17 Jun 2021 39.270 39.590 39.070 39.480 19,542,380 -
16 Jun 2021 39.620 39.840 39.280 39.300 19,166,590 -
15 Jun 2021 39.710 39.840 39.390 39.590 20,140,400 -
14 Jun 2021 40.030 40.070 39.380 39.630 23,390,920 -
11 Jun 2021 40.660 40.670 39.950 40.150 21,370,260 -
10 Jun 2021 39.900 40.720 39.890 40.680 42,589,920 -
09 Jun 2021 39.000 39.840 38.980 39.810 29,734,700 -
08 Jun 2021 39.070 39.110 38.475 38.850 18,861,770 -
07 Jun 2021 39.080 39.600 38.970 38.990 24,089,520 -
04 Jun 2021 39.050 39.500 39.015 39.150 19,355,010 -
03 Jun 2021 38.760 39.040 38.630 38.970 17,281,790 -
02 Jun 2021 38.640 38.930 38.540 38.790 19,604,540 -
01 Jun 2021 38.940 39.000 38.480 38.500 23,621,870 -
28 May 2021 38.750 39.020 38.680 38.730 16,148,150 -
27 May 2021 38.970 39.180 38.600 38.650 38,449,660 -
26 May 2021 39.290 39.300 38.780 38.920 28,016,360 -
25 May 2021 39.820 39.856 39.240 39.330 25,900,750 -
24 May 2021 40.080 40.140 39.775 39.810 16,906,250 -
Summary
Current 2 Weeks
(10 Jun 2021 to 23 Jun 2021)
39.900 40.720 38.700 39.050 241,208,600 -
Previous 2 Weeks
(26 May 2021 to 09 Jun 2021)
39.290 40.720 38.700 39.810 235,163,370 -
4 Weeks from
(28 Apr 2021 to 25 May 2021)
38.540 40.720 38.520 39.330 583,381,760 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.